tiprankstipranks
Trending News
More News >

Hoth Therapeutics Faces Nasdaq Compliance Challenge

Story Highlights
  • Hoth Therapeutics was notified of non-compliance with Nasdaq’s minimum bid price rule.
  • The company has until November 10, 2025, to regain compliance or face potential delisting.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Hoth Therapeutics Faces Nasdaq Compliance Challenge

Confident Investing Starts Here:

Hoth Therapeutics ( (HOTH) ) just unveiled an update.

On May 13, 2025, Hoth Therapeutics received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement of $1.00 per share. The company has until November 10, 2025, to regain compliance, with options like a reverse stock split under consideration to meet the Nasdaq listing rules.

The most recent analyst rating on (HOTH) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Hoth Therapeutics stock, see the HOTH Stock Forecast page.

More about Hoth Therapeutics

Hoth Therapeutics, Inc. operates in the biotechnology industry, focusing on developing therapies for dermatological disorders and other unmet medical needs.

Average Trading Volume: 645,782

Technical Sentiment Signal: Sell

Current Market Cap: $11.49M

Find detailed analytics on HOTH stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1